Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

Abstract

This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate-to-severe acute respiratory distress syndrome. Patients received a single 15 mL intravenous dose of ExoFlo and were evaluated for both safety and efficacy from days 1 to 14 post-treatment. All safety endpoints were met with no adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Overall, after one treatment, patients' clinical status and oxygenation improved with an average pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) increase of 192% (P < 0.001). Laboratory values revealed significant improvements in absolute neutrophil count [mean reduction 32% (P value <0.001)] and lymphopenia with average CD3+, CD4+, and CD8+ lymphocyte counts increasing by 46% (P < 0.05), 45% (P < 0.05), and 46% (P < 0.001), respectively. Likewise, acute phase reactants declined, with mean C-reactive protein, ferritin, and D-dimer reduction of 77% (P < 0.001), 43% (P < 0.001), and 42% (P < 0.05), respectively. In conclusion, owing to its safety profile, capacity to restore oxygenation, downregulate cytokine storm, and reconstitute immunity, ExoFlo is a promising therapeutic candidate for severe COVID-19. Future randomized controlled trials (RCTs) are needed to determine ExoFlo therapeutic potential.

Keywords: ARDS; COVID-19; MSC; SARS-CoV-2; bone marrow; exosome.

Conflict of interest statement

No competing financial interests exist.

Figures

FIG. 1.

Consort diagram for study enrollment, allocation of intervention, follow-up, and analysis.

FIG. 2.

Disposition or final study clinical status, partial PaO2/FiO2 ratio, in addition to oxygen requirement before and after administration of ExoFlo on days 1–14. Average PaO2/FiO2 ratio increase was 191% (P < 0.001) comparing baseline with 14 days after treatment or final known value. FiO2, fraction of inspired oxygen ratio; PaO2, pressure of arterial oxygen.

FIG. 3.

Acute phase reactants (CRP, ferritin, and D-dimer) and immune cell populations on day of treatment before IV administration of ExoFlo and on day 5 post-treatment. Mean reductions of CRP, ferritin, and D-dimer reductions were 77% (P < 0.001), 43% (P < 0.001), and 42% (P < 0.05), respectively. Mean reduction of ANC was 32% (P < 0.001); total lymphocyte count increased by 36% (P < 0.05) with CD3+, CD4+, and CD8+ T lymphocytes increased by 46% (P < 0.05), 45% (P < 0.05), and 46% (P < 0.001), respectively. ANC, absolute neutrophil count; CRP, C-reactive protein.